Cargando…
A prognostic 11-DNA methylation signature for lung squamous cell carcinoma
BACKGROUND: Lung squamous cell carcinoma (LUSC), as the second frequent subtype of lung cancer, causes lots of mortalities primarily due to a lack of precise prognostic markers and timely treatment intervention. Previous studies have constructed several risk prognostic models based on DNA methylatio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330303/ https://www.ncbi.nlm.nih.gov/pubmed/32642165 http://dx.doi.org/10.21037/jtd.2020.03.31 |
_version_ | 1783553089084588032 |
---|---|
author | Zhang, Jianlei Luo, Liyun Dong, Jing Liu, Meijun Zhai, Dongfeng Huang, Danqing Ling, Li Jia, Xiaoting Luo, Kai Zheng, Guopei |
author_facet | Zhang, Jianlei Luo, Liyun Dong, Jing Liu, Meijun Zhai, Dongfeng Huang, Danqing Ling, Li Jia, Xiaoting Luo, Kai Zheng, Guopei |
author_sort | Zhang, Jianlei |
collection | PubMed |
description | BACKGROUND: Lung squamous cell carcinoma (LUSC), as the second frequent subtype of lung cancer, causes lots of mortalities primarily due to a lack of precise prognostic markers and timely treatment intervention. Previous studies have constructed several risk prognostic models based on DNA methylation sites in multiple tumors, whereas, DNA methylation signature of LUSC remains to be built, and its predictive value need to be evaluated. METHODS: The genome-wide DNA methylation data of LUSC samples was obtained from The Cancer Genome Atlas dataset. Univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) were implemented to identify DNA methylation sites related to overall survival of LUSC patients. Thus, we performed multivariate Cox regression to establish a DNA methylation signature. The Kaplan-Meier (K-M) survival curves and time-dependent receiver operating characteristic (ROC) curves were plotted to estimate the prognostic power of the signature. Comparison with other known prognostic biomarkers, our DNA methylation signature showed higher predictive specificity and sensitivity. In addition, multivariate Cox regression screened out independent prognostic factors and constructed a nomogram. RESULTS: Several statistical methods were performed to construct an 11-DNA methylation signature. LUSC patients were divided into low- and high-risk group based on risk score, and high-risk group had a shorter survival time. According to the results of K-M and ROC analyses, the 11-DNA methylation signature showed significant sensitivity and specificity in predicting the LUSC patients’ overall survival. Finally, we integrated some independent prognostic factors (risk score, metastasis stage, and tobacco smoking history) to construct a nomogram, which has excellent prognostic power and may provide guidance for the therapeutic strategies. CONCLUSIONS: We constructed the first risk prognosis model based on DNA methylation site in LUSC, which showed better predictive ability. In addition, a nomogram integrating the DNA methylation signature, metastasis stage, and tobacco smoking history was developed. |
format | Online Article Text |
id | pubmed-7330303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-73303032020-07-07 A prognostic 11-DNA methylation signature for lung squamous cell carcinoma Zhang, Jianlei Luo, Liyun Dong, Jing Liu, Meijun Zhai, Dongfeng Huang, Danqing Ling, Li Jia, Xiaoting Luo, Kai Zheng, Guopei J Thorac Dis Original Article BACKGROUND: Lung squamous cell carcinoma (LUSC), as the second frequent subtype of lung cancer, causes lots of mortalities primarily due to a lack of precise prognostic markers and timely treatment intervention. Previous studies have constructed several risk prognostic models based on DNA methylation sites in multiple tumors, whereas, DNA methylation signature of LUSC remains to be built, and its predictive value need to be evaluated. METHODS: The genome-wide DNA methylation data of LUSC samples was obtained from The Cancer Genome Atlas dataset. Univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) were implemented to identify DNA methylation sites related to overall survival of LUSC patients. Thus, we performed multivariate Cox regression to establish a DNA methylation signature. The Kaplan-Meier (K-M) survival curves and time-dependent receiver operating characteristic (ROC) curves were plotted to estimate the prognostic power of the signature. Comparison with other known prognostic biomarkers, our DNA methylation signature showed higher predictive specificity and sensitivity. In addition, multivariate Cox regression screened out independent prognostic factors and constructed a nomogram. RESULTS: Several statistical methods were performed to construct an 11-DNA methylation signature. LUSC patients were divided into low- and high-risk group based on risk score, and high-risk group had a shorter survival time. According to the results of K-M and ROC analyses, the 11-DNA methylation signature showed significant sensitivity and specificity in predicting the LUSC patients’ overall survival. Finally, we integrated some independent prognostic factors (risk score, metastasis stage, and tobacco smoking history) to construct a nomogram, which has excellent prognostic power and may provide guidance for the therapeutic strategies. CONCLUSIONS: We constructed the first risk prognosis model based on DNA methylation site in LUSC, which showed better predictive ability. In addition, a nomogram integrating the DNA methylation signature, metastasis stage, and tobacco smoking history was developed. AME Publishing Company 2020-05 /pmc/articles/PMC7330303/ /pubmed/32642165 http://dx.doi.org/10.21037/jtd.2020.03.31 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zhang, Jianlei Luo, Liyun Dong, Jing Liu, Meijun Zhai, Dongfeng Huang, Danqing Ling, Li Jia, Xiaoting Luo, Kai Zheng, Guopei A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title | A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title_full | A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title_fullStr | A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title_full_unstemmed | A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title_short | A prognostic 11-DNA methylation signature for lung squamous cell carcinoma |
title_sort | prognostic 11-dna methylation signature for lung squamous cell carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330303/ https://www.ncbi.nlm.nih.gov/pubmed/32642165 http://dx.doi.org/10.21037/jtd.2020.03.31 |
work_keys_str_mv | AT zhangjianlei aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT luoliyun aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT dongjing aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT liumeijun aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT zhaidongfeng aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT huangdanqing aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT lingli aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT jiaxiaoting aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT luokai aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT zhengguopei aprognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT zhangjianlei prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT luoliyun prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT dongjing prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT liumeijun prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT zhaidongfeng prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT huangdanqing prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT lingli prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT jiaxiaoting prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT luokai prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma AT zhengguopei prognostic11dnamethylationsignatureforlungsquamouscellcarcinoma |